Hydroxyapatite-Targeting Multiarm Polymers for Bone Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for polymer reagents that can effectively target hydroxyapatite surfaces for drug delivery while maintaining timely clearance from the body, as existing polymer conjugates may be substantially inactive due to the length of the polymer chain wrapping around the active agent, limiting access to ligands required for pharmacologic activity.
Innovation Solution
The development of hydroxyapatite-targeting, linear or multiarm polymer reagents with degradable linkages and multiple hydroxyapatite-targeting moieties at the terminus, allowing for selective binding to hydroxyapatite surfaces and enhanced delivery of biologically active moieties to bone sites, while ensuring renal clearance and avoiding prolonged circulation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If a relatively long poly(ethylene glycol) molecule is attached to an active agent, then water solubility is improved, but the conjugate may become substantially inactive in vivo due to the polymer chain wrapping around the active agent and limiting access to ligands
Solution Approach 1:
The patent applies parameter changes by carefully controlling the molecular weight of PEG to fall within a specific range (500-20,000 Daltons) and optimizing the ratio of PEG to active agent (0.1:1 to 10:1). This quantitative optimization ensures the polymer provides sufficient solubility enhancement while maintaining the active agent's accessibility and pharmacologic activity, resolving the contradiction between solubility improvement and activity preservation.
2Duration of action of moving object
If a high molecular weight polymer is used to provide desirable in vivo circulation time, then circulation time is improved, but the polymer chain length may wrap around the active agent and limit ligand access
Solution Approach 1:
The patent resolves this contradiction by establishing a specific molecular weight range for PEG (500-20,000 Daltons) that optimizes the balance between circulation time and active agent accessibility. This parameter optimization ensures the polymer is long enough to provide extended circulation but short enough to avoid wrapping around and blocking the active agent's ligands.
Solution Approach 2:
The patent applies partial action by using a moderate amount of PEG rather than excessive polymerization. The optimized PEG:active agent ratio (0.1:1 to 10:1) provides sufficient circulation time enhancement without over-polymerization that would cause the chain to wrap around and inhibit ligand access, achieving the desired effect with controlled, partial polymerization.
3Stability of the object's composition
If end-capped PEG is used to reduce cross-linking and aggregation, then polymer stability is improved, but the end-capping groups may interfere with conjugation reactions
Solution Approach 1:
The patent applies local quality by using end-capped PEG where only the terminal hydroxyl groups are capped while the internal ether oxygens remain available for conjugation reactions. This localized modification provides stability at the chain ends while preserving reactivity at other positions, resolving the contradiction between polymer stability and conjugation efficiency.
Solution Approach 2:
The patent applies multi-functionality by designing end-capped PEG that simultaneously provides stability (through end-capping that prevents cross-linking and aggregation) and conjugation capability (through available internal ether oxygens and controlled end-group chemistry). The polymer structure performs multiple functions: stabilizing the conjugate, enabling solubility, and providing controlled reactivity for drug attachment.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The polymer reagents effectively target and bind to hydroxyapatite surfaces, increasing the concentration of biologically active agents at the bone site, ensuring timely delivery and clearance, thereby overcoming the limitations of existing polymer conjugates.
Implementation Method 1
The polymer reagents effectively target and bind to hydroxyapatite surfaces, increasing the concentration of biologically active agents at the bone site
Data Source
AI summary
The present invention provides, among other things, polymeric reagents suitable for reaction with biologically active agents to form conjugates, the polymeric reagents comprising one or more polymer chains and a plurality of hydroxyapatite-targeting moieties, and optionally the reagents include one or more degradable linkages that serve to divide the polymer chains into polymer segments having a molecular weight suitable for renal clearance.